Medtronic Reports Strongest Annual Revenue Growth in Decade

What happened

Medtronic announced fiscal Q4 and full-year 2026 results on June 3, reporting Q4 revenue of $9.8 billion (up 9.9%) and full-year revenue of $36.364 billion (up 8.4%). The cardiovascular segment grew 10.1%, led by 78% global growth in cardiac ablation solutions, including 124% U.S. growth. Medical surgical advanced 5.1%, driven by acute care and endoscopy products. The company achieved $1.55 non-GAAP EPS in Q4 and $0.96 GAAP EPS (up 17%). Medtronic generated $7.3 billion in operating cash flow and $5.4 billion in free cash flow for the year, representing 76% conversion from non-GAAP net earnings. The board approved a dividend increase to $0.72 per share quarterly (annualized $2.88), marking the 49th consecutive year of dividend increases. The company returned $4.2 billion to shareholders through dividends and repurchases. Medtronic completed the CathWorks acquisition and announced plans to acquire Scientia Vascular and SPR Therapeutics, while securing multiple FDA clearances, including for the Stealth AXiS Surgical System and ProGrip Advanced. Separately, its MiniMed diabetes unit reported a $183 million net loss despite better-than-expected sales.

Why it matters

The results mark Medtronic's strongest annual revenue growth in a decade, signaling accelerated momentum in key franchises and new product cycles. The cardiovascular segment's third consecutive quarter of double-digit growth demonstrates the success of recent product launches and acquisitions, particularly in cardiac ablation and rhythm management. The 49th consecutive year of dividend increases reinforces the company's long-term commitment to shareholder returns, supported by strong cash generation. FDA clearances and regulatory progress across multiple product lines expand addressable markets and competitive positioning. The company's active M&A strategy-completing CathWorks and announcing deals for Scientia Vascular and SPR Therapeutics-aims to fill pipeline gaps and accelerate growth in high-potential areas. However, fiscal 2027 guidance for 6.75% to 7.25% organic revenue growth came in below some analyst expectations, and the company continues to face operational challenges, including a cyberattack in April and facility closures affecting 370 employees in May. The MiniMed diabetes unit's $183 million loss highlights ongoing challenges in that segment, which IPO'd below its marketed range in March.

Bigger picture

Medtronic's results reflect broader strength in the global medical device market, driven by aging demographics, expanding access to advanced therapies, and post-pandemic procedure recovery. The company's cardiovascular and surgical businesses are benefiting from innovation in minimally invasive and robotic-assisted technologies, a competitive battleground also occupied by peers such as Abbott, Boston Scientific, and Intuitive Surgical. The cardiac ablation market, where Medtronic achieved 78% growth, is experiencing rapid expansion as electrophysiology procedures increase and new therapies gain regulatory approval. Medtronic's active M&A strategy mirrors industry-wide consolidation, as large players seek to acquire emerging technologies and sustain growth momentum. Operational challenges-including cyberattacks affecting Medtronic, Stryker, and Intuitive Surgical in recent months-underscore rising cybersecurity risks across the healthcare technology sector. The company's 49-year dividend track record positions it as a stability play in a sector increasingly dominated by high-growth, high-valuation peers. Tariff impacts referenced in guidance reflect macroeconomic headwinds affecting multinational manufacturers.

What to watch

Monitor fiscal 2027 organic revenue growth relative to the 6.75% to 7.25% guidance, particularly cardiovascular segment momentum and whether growth rates stabilize or accelerate. Track regulatory progress on Hugo RAS for general surgery and gynecologic indications, and the Stealth AXiS rollout in spine, cranial, and ENT markets. Watch for updates on the Scientia Vascular and SPR Therapeutics acquisitions and integration progress. Observe MiniMed's path to profitability and whether the diabetes unit can stabilize after its underwhelming IPO performance. Monitor tariff impacts on margins and pricing strategies in international markets. Keep an eye on potential product recalls or quality issues, which have historically affected Medtronic's operations. Quarterly updates on cash generation, share repurchases, and dividend sustainability will remain important for income-focused investors. Analyst price target adjustments and peer performance comparisons, especially in cardiovascular and robotic-assisted surgery, will offer additional context.